Wheat germ cell-free technology for accelerating the malaria vaccine research

Expert Opinion on Drug Discovery

Volumn 4, Issue 11, 2009, Pages 1191-1199

  Takeo, Satoru ^a   Arumugam, Thangavelu U ^a   Torii, Motomi ^b   Tsuboi, Takafumi ^a  

^a EHIME UNIVERSITY   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Malaria; Plasmodium falciparum; Post genome; Vaccine candidate discovery; Wheat germ cell free protein synthesis

Indexed keywords

CELL PROTEIN; MALARIA VACCINE;

DRUG EFFICACY; DRUG QUALITY; DRUG RESEARCH; DRUG SCREENING; DRUG SYNTHESIS; GENOME; GERM CELL; HUMAN; MALARIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; WHEAT GERM;

EID: 72949113479     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440903369813     Document Type: Review

References (80)

1. WHO. World Malaria Report 2008. Geneva, Switzerland: WHO Press; 2008
2. Miller LH, Baruch DI, Marsh K, et al. The pathogenic basis of malaria. Nature 2002;415:673-679
3. Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol 2006;28:51-60
4. Genton B. Malaria vaccines: a toy for travelers or a tool for eradication? Expert Rev Vaccines 2008;7:597-611
5. Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev 2009;22:13-36, Table of Contents
6. Cohen S, Mc GI, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961;192:733-737
7. McGregor IA. The passive transfer of human malaria immunity. Am J Trop Med Hyg 1964;13(Suppl):237-239
8. Gupta S, Snow RW, Donnelly CA, et al. Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat Med 1999;5:340-343
9. Pombo DJ, Lawrence G, Hirunpetcharat C, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with plasmodium falciparum. Lancet 2002;360:610-617
10. Nussenzweig RS, Vanderberg J, Most H, et al. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature 1967;216:160-162
11. Hoffman SL, Goh LM, Luke TC, et al. Protection of humans against malaria by immunization with radiation-attenuated plasmodium falciparum sporozoites. J Infect Dis 2002;185:1155-1164
12. Roestenberg M, McCall M, Hopman J, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009;361:468-477
13. Greenwood B, Mutabingwa T. Malaria in 2002. Nature 2002;415:670-672
14. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in plasmodium falciparum malaria. N Engl J Med 2009;361:455-467
15. Greenwood B. Can malaria be eliminated? Trans R Soc Trop Med Hyg 2009;103(Suppl 1):S2-5
16. Richie TL, Saul A. Progress and challenges for malaria vaccines. Nature 2002;415:694-701
17. Greenwood BM, Fidock DA, Kyle DE, et al. Malaria: progress, perils, and prospects for eradication. J Clin Invest 2008;118:1266-1276
18. Stoute JA, Slaoui M, Heppner DG, et al.; RTS,S Malaria Vaccine Evaluation Group. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against plasmodium falciparum malaria. N Engl J Med 1997;336:86-91
19. Heppner DG Jr, Kester KE, Ockenhouse CF, et al. Towards an RTS, S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 2005;23:2243-2250
20. Alonso PL, Sacarlal J, Aponte JJ, et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005;366:2012-2018
21. Aponte JJ, Aide P, Renom M, et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 2007;370:1543-1551
22. Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008;359:2521-2532
23. Miller LH, Mason SJ, Clyde DF, et al. The resistance factor to plasmodium vivax in blacks. The duffy-blood-group genotype, FyFy. N Engl J Med 1976;295:302-304
24. Ling IT, Ogun SA, Holder AA. Immunization against malaria with a recombinant protein. Parasite Immunol 1994;16:63-67
25. Perera KL, Handunnetti SM, Holm I, et al. Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human plasmodium vivax malaria. Infect Immun 1998;66:1500-1506
26. Crewther PE, Matthew ML, Flegg RH, et al. Protective immune responses to apical membrane antigen 1 of plasmodium chabaudi involve recognition of strain-specific epitopes. Infect Immun 1996;64:3310-3317
27. Collins WE, Pye D, Crewther PE, et al. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of plasmodium fragile. Am J Trop Med Hyg 1994;51:711-719
28. Richards JS, Beeson JG. The future for blood-stage vaccines against malaria. Immunol Cell Biol 2009;87:377-390
29. Baum J, Maier AG, Good RT, et al. Invasion by P. falciparum merozoites suggests a hierarchy of molecular interactions. PLoS Pathog 2005;1:e37
30. Cowman AF, Crabb BS. Invasion of red blood cells by malaria parasites. Cell 2006;124:755-766
31. Maier AG, Cooke BM, Cowman AF, et al. Malaria parasite proteins that remodel the host erythrocyte. Nat Rev Microbiol 2009;7:341-354
32. Fried M, Duffy PE. Adherence of plasmodium falciparum to chondroitin sulfate A in the human placenta. Science 1996;272:1502-1504
33. Fried M, Nosten F, Brockman A, et al. Maternal antibodies block malaria. Nature 1998;395:851-852
34. Francis SE, Malkov VA, Oleinikov AV, et al. Six genes are preferentially transcribed by the circulating and sequestered forms of plasmodium falciparum parasites that infect pregnant women. Infect Immun 2007;75:4838-4850
35. Salanti A, Staalsoe T, Lavstsen T, et al. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol 2003;49:179-191
36. Viebig NK, Gamain B, Scheidig C, et al. A single member of the plasmodium falciparum var multigene family determines cytoadhesion to the placental receptor chondroitin sulphate A. EMBO Rep 2005;6:775-781
37. Gamain B, Trimnell AR, Scheidig C, et al. Identification of multiple chondroitin sulfate A (CSA)-binding domains in the var2CSA gene transcribed in CSA-binding parasites. J Infect Dis 2005;191:1010-1013
38. Duffy PE. Plasmodium in the placenta: parasites, parity, protection, prevention and possibly preeclampsia. Parasitology 2007;134:1877-1881
39. Feachem R, Sabot O. A new global malaria eradication strategy. Lancet 2008;371:1633-1635
40. Carter R. Transmission blocking malaria vaccines. Vaccine 2001;19:2309-2314
41. Hisaeda H, Stowers AW, Tsuboi T, et al. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of plasmodium vivax to infect mosquitoes. Infect Immun 2000;68:6618-6623
42. Wu Y, Przysiecki C, Flanagan E, et al. Sustained high-titer antibody responses induced by conjugating a malaria vaccine candidate to outer-membrane protein complex. Proc Natl Acad Sci USA 2006;103:18243-18248
43. Wu Y, Ellis RD, Shaffer D, et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 2008;3:e2636
44. Malkin EM, Durbin AP, Diemert DJ, et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for plasmodium vivax malaria. Vaccine 2005;23:3131-3138
45. Smith TA, Leuenberger R, Lengeler C. Child mortality and malaria transmission intensity in Africa. Trends Parasitol 2001;17:145-149
46. Targett GA, Greenwood BM. Malaria vaccines and their potential role in the elimination of malaria. Malar J 2008;7(Suppl 1):S10
47. Lasonder E, Ishihama Y, Andersen JS, et al. Analysis of the plasmodium falciparum proteome by high-accuracy mass spectrometry. Nature 2002;419:537-542
48. Gardner MJ, Hall N, Fung E, et al. Genome sequence of the human malaria parasite plasmodium falciparum. Nature 2002;419:498-511
49. Carlton JM, Adams JH, Silva JC, et al. Comparative genomics of the neglected human malaria parasite plasmodium vivax. Nature 2008;455:757-763
50. Pain A, Bohme U, Berry AE, et al. The genome of the simian and human malaria parasite plasmodium knowlesi. Nature 2008;455:799-803
51. Carlton JM, Angiuoli SV, Suh BB, et al. Genome sequence and comparative analysis of the model rodent malaria parasite plasmodium yoelii yoelii. Nature 2002;419:512-519
52. Flower D. Bioinformatics for Vaccinology. Chichester, West Sussex, UK: John Wiley & Sons; 2008
53. Hall N, Karras M, Raine JD, et al. A comprehensive survey of the Plasmodium life cycle by genomic, transcriptomic, and proteomic analyses. Science 2005;307:82-86
54. Sim BK, Chitnis CE, Wasniowska K, et al. Receptor and ligand domains for invasion of erythrocytes by plasmodium falciparum. Science 1994;264:1941-1944
55. Mu J, Awadalla P, Duan J, et al. Genome-wide variation and identification of vaccine targets in the plasmodium falciparum genome. Nat Genet 2007;39:126-130
56. Doolan DL, Mu Y, Unal B, et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 2008;8:4680-4694
57. Aguiar JC, LaBaer J, Blair PL, et al. High-throughput generation of P. falciparum functional molecules by recombinational cloning. Genome Res 2004;14:2076-2082
58. Mehlin C, Boni E, Buckner FS, et al. Heterologous expression of proteins from plasmodium falciparum: results from 1000 genes. Mol Biochem Parasitol 2006;148:144-160
59. Vedadi M, Lew J, Artz J, et al. Genome-scale protein expression and structural biology of plasmodium falciparum and related apicomplexan organisms. Mol Biochem Parasitol 2007;151:100-110
60. Gowda DC, Davidson EA. Protein glycosylation in the malaria parasite. Parasitol Today 1999;15:147-152
61. Kedees MH, Azzouz N, Gerold P, et al. Plasmodium falciparum: glycosylation status of plasmodium falciparum circumsporozoite protein expressed in the baculovirus system. Exp Parasitol 2002;101:64-68
62. Samuelson J, Banerjee S, Magnelli P, et al. The diversity of dolichol-linked precursors to Asn-linked glycans likely results from secondary loss of sets of glycosyltransferases. Proc Natl Acad Sci USA 2005;102:1548-1553
63. Tsuboi T, Takeo S, Iriko H, et al. Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates. Infect Immun 2008;76:1702-1708
64. Madin K, Sawasaki T, Ogasawara T, et al. A highly efficient and robust cell-free protein synthesis system prepared from wheat embryos: plants apparently contain a suicide system directed at ribosomes. Proc Natl Acad Sci USA 2000;97:559-564
65. Endo Y, Sawasaki T. Cell-free expression systems for eukaryotic protein production. Curr Opin Biotechnol 2006;17:373-380
66. Goshima N, Kawamura Y, Fukumoto A, et al. Human protein factory for converting the transcriptome into an in vitro-expressed proteome. Nat Methods 2008;5:1011-1017
67. Sawasaki T, Ogasawara T, Morishita R, et al. A cell-free protein synthesis system for high-throughput proteomics. Proc Natl Acad Sci USA 2002;99:14652-14657
68. Sawasaki T, Endo Y. The wheat germ cell-free protein synthesis system. In: Spirin AS, Swartz JR, editors, Cell-free protein synthesis, methods and protocols. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 2008. p. 111-139
69. Sawasaki T, Gouda MD, Kawasaki T, et al. The wheat germ cell-free expression system: methods for high-throughput materialization of genetic information. Methods Mol Biol 2005;310:131-144
70. Kamura N, Sawasaki T, Kasahara Y, et al. Selection of 5¢-untranslated sequences that enhance initiation of translation in a cell-free protein synthesis system from wheat embryos. Bioorg Med Chem Lett 2005;15:5402-5406
71. Vinarov DA, Lytle BL, Peterson FC, et al. Cell-free protein production and labeling protocol for NMR-based structural proteomics. Nat Methods 2004;1:149-153
72. Mudeppa DG, Pang CK, Tsuboi T, et al. Cell-free production of functional plasmodium falciparum dihydrofolate reductase-thymidylate synthase. Mol Biochem Parasitol 2007;151:216-219
73. Takeo S, Hisamori D, Matsuda S, et al. Enzymatic characterization of the plasmodium vivax chitinase, a potential malaria transmission-blocking target. Parasitol Int 2009:58;243-248
74. Maeda T, Saito T, Harb OS, et al. Pyruvate kinase type-II isozyme in plasmodium falciparum localizes to the apicoplast. Parasitol Int 2009;58:101-105
75. VanBuskirk KM, O'Neill MT, De La Vega P, et al. Preerythrocytic, live-attenuated plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci USA 2009: 106;13004-13009
76. Cao J, Kaneko O, Thongkukiatkul A, et al. Rhoptry neck protein RON2 forms a complex with microneme protein AMA1 in plasmodium falciparum merozoites. Parasitol Int 2009;58:29-35
77. Otsuki H, Kaneko O, Thongkukiatkul A, et al. Single amino acid substitution in plasmodium yoelii erythrocyte ligand determines its localization and controls parasite virulence. Proc Natl Acad Sci USA 2009;106:7167-7172
78. Dutta S, Lalitha PV, Ware LA, et al. Purification, characterization, and immunogenicity of the refolded ectodomain of the plasmodium falciparum apical membrane antigen 1 expressed in escherichia coli. Infect Immun 2002;70:3101-3110
79. Netzer WJ, Hartl FU. Recombination of protein domains facilitated by co-translational folding in eukaryotes. Nature 1997;388:343-349
80. Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002;295:1852-1858